People in the study are assigned by chance to receive different doses of ICP-332 or placebo. The treatment is taken over a period of time, and the study team follows participants during the trial to see how the skin condition and itching change and to watch for any side effects. The medicine being tested has the code name ICP-332 and the active substance is 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE.

The purpose of this research is to evaluate how well different doses of Rocatinlimab work compared to placebo in reducing itching in people with Prurigo Nodularis. The medication will be given as a subcutaneous injection (an injection under the skin). The study will last for 52 weeks, during which participants will receive either Rocatinlimab or placebo.

Throughout the study, participants will need to keep a daily record of their symptoms, including itching intensity and skin pain. Doctors will regularly examine the skin nodules and monitor how the treatment affects participants’ quality of life and sleep. The study will also track any side effects that may occur during the treatment period.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The treatment will be administered in the form of tablets taken orally, and the study will last for a period of up to 48 weeks.

Throughout the study, participants will be monitored to assess the effectiveness and safety of Povorcitinib. The main goal is to see if there is a significant improvement in the itchiness and appearance of the skin lesions by the end of the study period. Participants will have regular check-ups to track their progress and any changes in their condition.

The purpose of the study is to determine how well Ruxolitinib cream works in treating Prurigo Nodularis. Participants in the study will be randomly assigned to receive either the Ruxolitinib cream or a vehicle cream, which looks and feels like the Ruxolitinib cream but does not contain the active medication. This helps researchers compare the effects of the actual medication against a cream without the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the Ruxolitinib cream and who is receiving the vehicle cream, to ensure unbiased results.

Throughout the study, participants will apply the cream to their skin as directed and attend regular check-ups to monitor their progress. The study will last for several weeks, with key assessments at different points to evaluate improvements in symptoms. The main goal is to see if there is a significant reduction in itchiness and skin lesions after using the Ruxolitinib cream compared to the vehicle cream. Participants’ experiences and any changes in their condition will be carefully recorded to help determine the treatment’s effectiveness and safety.

The purpose of this research is to evaluate the long-term safety of Povorcitinib in people who have previously participated in other studies of this medication. The study will continue for up to 36 months, during which participants will continue taking the medication and have their condition monitored.

This is a follow-up study specifically designed for individuals who have already completed treatment with Povorcitinib in previous research studies and have shown improvement in their condition. Throughout the study, doctors will monitor how well the medication continues to work and check for any side effects that might occur with long-term use.

Participants in the study will receive injections of either dupilumab or a placebo. The study is designed to compare the effects of dupilumab with those of the placebo over a period of 24 weeks. During this time, participants will be monitored to see if there is an improvement in their symptoms, particularly the reduction of itching. The study will also look at how the treatment affects sleep disturbances caused by itching and overall quality of life.

The purpose of this study is to demonstrate the effectiveness of dupilumab in treating moderate-to-severe LSC in adults who have not responded well to other treatments. Participants will be assessed regularly to track changes in their symptoms and any side effects they may experience. The study will help determine if dupilumab can be a beneficial treatment option for those suffering from this persistent skin condition.

The purpose of the study is to assess the effectiveness and safety of Povorcitinib. Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of 48 weeks, during which participants will take the medication orally. Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms.

By participating in this study, researchers aim to gather important information about how Povorcitinib can help manage the symptoms of Prurigo Nodularis. The ultimate goal is to find a treatment that can provide relief from the intense itching and improve the quality of life for those affected by this condition.

The purpose of the study is to assess the effectiveness and safety of Barzolvolimab in treating the itch associated with Prurigo Nodularis. Participants in the study will receive either Barzolvolimab or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will last for several weeks, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will be asked to keep a daily diary to record their itch levels and any other symptoms. The main goal is to see if there is a significant improvement in the itchiness experienced by participants taking Barzolvolimab compared to those taking the placebo. The study will also look at other factors, such as the overall condition of the skin and any changes in quality of life. Participants will have regular check-ups with the study team to ensure their safety and to track their progress.

Participants in the study will receive Nemolizumab injections over a period of time. Some participants may receive a placebo instead. The study will monitor the safety of the treatment and how well it works in reducing the symptoms of Prurigo Nodularis. Participants will have regular visits to the study site to receive their injections and to have their health and symptoms checked by the study team.

The study will last for several years, allowing researchers to gather information on the long-term effects of Nemolizumab. Participants will be asked to record their symptoms and any changes they notice using a handheld electronic device provided by the study. This information will help researchers understand how Nemolizumab affects Prurigo Nodularis over time and whether it is a safe and effective treatment option for this condition.

The purpose of the study is to determine how well the Ruxolitinib cream works in treating Prurigo Nodularis. Participants in the study will be randomly assigned to receive either the Ruxolitinib cream or a vehicle cream, which looks and feels like the Ruxolitinib cream but does not contain the active medication. This helps researchers compare the effects of the actual medication against a cream without the active ingredient.

The study will last for several weeks, during which participants will apply the cream to their skin as directed. Throughout the study, participants will be monitored to assess any changes in their skin condition and to ensure their safety. The study aims to provide valuable information on whether Ruxolitinib cream can be an effective treatment option for those suffering from Prurigo Nodularis.